The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis

被引：30
作者：
Lockhart, I. A. [1 ]
Orme, M. E. [2 ]
Mitchell, S. A. [3 ]
机构：
[1] Pfizer Ltd, Walton Oaks Dorking Rd,Walton Hill, Tadworth KT20 7NS, England
[2] ICERA Consulting Ltd, Swindon, Wilts, England
[3] Abacus Int, Bicester, Oxon, England
来源：
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2011年 / 1卷 / 01期
关键词：
Alzheimer disease; Behavioural/psychiatric symptoms of dementia; Behavioural medicine; Community Mental Health Services; Geriatric psychiatry; Home nursing; Meta-analysis; Preventive psychiatry; Systematic reviews;
D O I：
10.1159/000330032
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI -3.51, 95% confidence interval (CI) -5.75, -1.27], whereas this was not the case for memantine (WMD -1.65, 95% CI -4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (-1.86, 95% CI -5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：212 / 227
页数：16
相关论文
共 52 条
  • [31] Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis
    Maidment, Ian D.
    Fox, Chris G.
    Boustani, Malaz
    Rodriguez, Jorge
    Brown, Ruth C.
    Katona, Cornelius L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2008, 42 (01) : 32 - 38
  • [32] Margallo-Lana M, 2001, INT J GERIATR PSYCH, V16, P39, DOI 10.1002/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO
  • [33] 2-F
  • [34] Behavioural changes and psychological symptoms in dementia disorders
    McKeith, I
    Cummings, J
    [J]. LANCET NEUROLOGY, 2005, 4 (11) : 735 - 742
  • [35] The spectrum of behavioral changes in Alzheimer's disease
    Mega, MS
    Cummings, JL
    Fiorello, T
    Gornbein, J
    [J]. NEUROLOGY, 1996, 46 (01) : 130 - 135
  • [36] O'Donnell B F, 1992, J Geriatr Psychiatry Neurol, V5, P45
  • [37] Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
    Peskind, Elaine R.
    Potkin, Steven G.
    Pomara, Nunzio
    Ott, Brian R.
    Graham, Stephen M.
    Olin, Jason T.
    McDonald, Scott
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (08) : 704 - 715
  • [38] Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial
    Porsteinsson, Anton P.
    Grossberg, George T.
    Mintzer, Jacobo
    Olin, Jason T.
    [J]. CURRENT ALZHEIMER RESEARCH, 2008, 5 (01) : 83 - 89
  • [39] Memantine in moderate-to-severe Alzheimer's disease
    Reisberg, B
    Doody, R
    Stoffler, A
    Schmitt, F
    Ferris, S
    Mobius, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) : 1333 - 1341
  • [40] Antipsychotic therapy and short-term serious events in older adults with dementia
    Rochon, Paula A.
    Normand, Sharon-Lise
    Gomes, Tara
    Gill, Sudeep S.
    Anderson, Geoffrey M.
    Melo, Magda
    Sykora, Kathy
    Lipscombe, Lorraine
    Bell, Chaim M.
    Gurwitz, Jerry H.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (10) : 1090 - 1096
123456